Antithrombotic Therapy

November 26, 2022

The November 2022 cardiology month in review features the top content from AHA Scientific Sessions 2022, new data related to use of direct oral anticoagulation, and an FDA warning to companies over violations of the FD&C Act.

November 25, 2022

Results of the RIDTS study suggest extending anticoagulation with rivaroxaban to 12 weeks as opposed to the traditional 6-week course could reduce recurrent venous thromboembolism in patients with symptomatic isolated DVT.

November 21, 2022

An analysis of data from Medicare beneficiaries receiving treatment over a decade-long period provides a snapshot of oral anticoagulation initiation and nonadherence among older patients with atrial fibrillation in the US.

November 17, 2022

Using data from 88 medical centers across the US, new data is providing clinicians with an overview of contemporary trends in DOAC and warfarin use in adult patients with nonvalvular atrial fibrillation at high risk for stroke over the past decade.

November 04, 2022

Data from a phase 3 trial presented at AHA 22 suggests use of edoxaban could be a safe and effective method for reducing risk of thromboembolism in pediatric patients with cardiovascular disease considered to be at increased risk of thrombosis.

October 29, 2022

The October 2022 cardiology month in review features the top content from HFSA 2022, new data related to antithrombotic therapy in atrial fibrillation, and shining a spotlight on the AHA’s scientific statement on patient-reported outcomes in peripheral artery disease.

October 28, 2022

An analysis of the GWTG-Atrial Fibrillation Registry data suggests Black patients with AFib were 25% less likely to receive a prescription for oral anticoagulation at discharge and 27% less likely to receive a DOAC than their non-Hispanic White counterparts.

October 27, 2022

An analysis of data from a quality improvement initiative demonstrates the majority of patients continue their anticoagulant regimen beyond the guideline-directed 3 months following provoked VTE.

October 18, 2022

An analysis of claims data from a 7-year period provides insight into the rate of ischemic stroke or systemic embolism and bleeding events with 2 popular DOACs in people with atrial fibrillation and valvular heart disease.

September 03, 2022

Although the European Society of Cardiology (ESC) Congress 2022 may be over, our editorial team is recapping the most popular new trial data from the ESC’s first in-person conference since 2019. The top 5 trials, which were chosen based on total views per article, includes DELIVER, TIME, AXIOMATIC-SSP, FIDELITY, and DANCAVAS.